CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6402 result(s)

semaglutide (Ozempic)

Last Updated: June 18, 2019
Result type: Reports
Product Line: Reimbursement Review
Generic Name: semaglutide
Indications: Diabetes mellitus, type 2

  • Brand Name: Ozempic
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0594-000
  • Project Status: Complete
  • Submission Type: Initial

patiromer (Veltassa)

Last Updated: May 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: patiromer
Indications: For the treatment of hyperkalemia in adults with chronic kidney disease (eGFR ≥15mL/min/1.73m).

  • Brand Name: Veltassa
  • Manufacturer: Otsuka Canada Pharmaceuticals Inc.
  • Project Number: SR0665-000
  • Project Status: Active
  • Submission Type: Initial

semaglutide (Rybelsus)

Last Updated: May 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: semaglutide
Indications: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in combination with other medicinal products for the treatment of diabetes

  • Brand Name: Rybelsus
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0637-000
  • Project Status: Active
  • Submission Type: Initial

dupilumab (Dupixent)

Last Updated: May 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dupilumab
Indications: Dupixent is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.

  • Brand Name: Dupixent
  • Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0667-000
  • Project Status: Active
  • Submission Type: Initial

risdiplam (Evrysdi)

Last Updated: May 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: risdiplam
Indications: ​For the treatment of spinal muscular atrophy (SMA) in patients 2 months and older.

  • Brand Name: Evrysdi
  • Manufacturer: Hoffmann La-Roche Ltd.
  • Project Number: SR0661-000
  • Project Status: Active
  • Submission Type: Initial

tralokinumab (TBC)

Last Updated: May 12, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: tralokinumab
Indications: Tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. TRADENAME (tralokinumab) can be used with or without topical corticosteroids.

  • Brand Name: TBC
  • Manufacturer: LEO Pharma Inc.
  • Project Number: SR0689-000
  • Project Status: Active
  • Submission Type: Initial

von Willebrand Factor [recombinant] (Vonvendi)

Last Updated: May 12, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: von Willebrand Factor [recombinant]
Indications: ​Indicated for: Treatment and Control of bleeding episodes in adults (age ≥18) diagnosed with von Willebrand Disease (VWD).Perioperative management of bleeding in adults (age ≥18) diagnosed with VWD

  • Brand Name: Vonvendi
  • Manufacturer: Shire Pharma Canada ULC, now part of Takeda
  • Project Number: ST0639-000
  • Project Status: Complete
  • Submission Type: Initial